194 related articles for article (PubMed ID: 29520981)
1. Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
Ito S; Hosaka T; Yano W; Itou T; Yasumura M; Shimizu Y; Kobayashi H; Nakagawa T; Inoue K; Tanabe S; Kondo T; Ishida H
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29520981
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
[TBL] [Abstract][Full Text] [Related]
3. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Matsubayashi Y; Yoshida A; Suganami H; Osawa T; Furukawa K; Suzuki H; Fujihara K; Tanaka S; Kaku K; Sone H
Diabetes Obes Metab; 2020 Jun; 22(6):947-956. PubMed ID: 31984623
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
Diabetes Obes Metab; 2019 Jul; 21(7):1715-1724. PubMed ID: 30945431
[TBL] [Abstract][Full Text] [Related]
5. A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor.
Fujita Y; Atageldiyeva KK; Takeda Y; Yanagimachi T; Makino Y; Haneda M
Front Endocrinol (Lausanne); 2020; 11():601594. PubMed ID: 33362717
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
[TBL] [Abstract][Full Text] [Related]
8. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
Ishibashi Y; Matsui T; Yamagishi SI
Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285
[TBL] [Abstract][Full Text] [Related]
10. Tofogliflozin: first global approval.
Poole RM; Prossler JE
Drugs; 2014 Jun; 74(8):939-44. PubMed ID: 24848755
[TBL] [Abstract][Full Text] [Related]
11. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
Sato Y; Nunoi K; Kaku K; Yoshida A; Suganami H
Diabetes Obes Metab; 2020 Feb; 22(2):222-230. PubMed ID: 31608549
[TBL] [Abstract][Full Text] [Related]
12. Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice.
Joki Y; Konishi H; Takasu K; Minamino T
J Cardiol; 2023 Apr; 81(4):347-355. PubMed ID: 36244565
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Tahara A; Takasu T
Life Sci; 2018 Mar; 197():80-90. PubMed ID: 29425766
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
15. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
Babar M; Hussain M; Ahmad M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin.
Watanabe Y; Suzuki D; Kuribayashi N; Uchida D; Kato M; Ohashi H; Nagayama D; Yamaguchi T; Ohira M; Saiki A; Tatsuno I
Sci Rep; 2021 May; 11(1):11350. PubMed ID: 34059720
[TBL] [Abstract][Full Text] [Related]
17. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
18. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial.
Tay J; Luscombe-Marsh ND; Thompson CH; Noakes M; Buckley JD; Wittert GA; Yancy WS; Brinkworth GD
Am J Clin Nutr; 2015 Oct; 102(4):780-90. PubMed ID: 26224300
[TBL] [Abstract][Full Text] [Related]
19. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
20. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
